Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

265 trials

NCT07428707
Recruiting
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
Early phase 1 · United States · 1 site
Registry update: 22 Oct 2026
NCT07424833
Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Phase 1 · China, United States · 6 sites
Registry update: 15 Oct 2026
NCT07218341
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 4 · Austria, Australia, Belgium, Canada, China, Czechia, Spain, France, United Kingdom, Croatia, Hungary, Ireland, Israel, Italy, Japan, Poland, United States · 50 sites
Registry update: 4 Nov 2026
NCT07290309
Recruiting
Survivors Uniting for Remote Guided Exercise
Not applicable · United States · 1 site
Registry update: 31 Mar 2026
NCT07277231
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3 · Australia, Brazil, Canada, China, Czechia, Germany, Spain, France, United Kingdom, Italy, South Korea, Netherlands, New Zealand, Poland, Romania, Sweden, United States · 117 sites
Registry update: 28 Sept 2026
NCT07422337
Recruiting
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Not applicable · United States · 2 sites
Registry update: 28 Oct 2026
NCT07218510
Recruiting
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
Phase 2 · United States · 7 sites
Registry update: 13 Mar 2026
NCT07313982
Recruiting
LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION
Not applicable · Italy · 1 site
Registry update: 2 Jan 2026
NCT07288515
Recruiting
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
Not applicable · Belarus · 4 sites
Registry update: 9 Sept 2026
2024-512503-39-00
Recruiting
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Phase 4 · Germany, France, Italy, Poland · 53 sites
Registry update: 1 Oct 2026
NCT07774390
Recruiting
Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL
Not applicable · Italy · 1 site
Registry update: 19 Aug 2026
2025-521735-36-00
Recruiting
QUADvance: Advancing Allogeneic Quad-CAR01-T Therapy in Hard-to-Treat B-Cell Cancers
Phase 1/2 · Germany · 8 sites
Registry update: 30 Sept 2026
NCT07014917
Recruiting
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Phase 2 · United States · 1 site
Registry update: 6 Jan 2026
NCT06958705
Recruiting
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Phase 2 · China · 1 site
Registry update: 25 Nov 2025
NCT07052695
Recruiting
Mosunetuzumab for CLL MRD Clearance
Phase 1/2 · United States · 2 sites
Registry update: 15 Dec 2025
NCT07638007
Recruiting
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Not applicable · United States · 1 site
Registry update: 10 Jun 2026
NCT07313878
Recruiting
Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Microscopy
Not applicable · Germany · 1 site
Registry update: 2 Jan 2026
2025-521088-10-00
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a Bcell Lymphoma-2 Inhibitor (BCL-2i) (DAYBreak CLL-201)
Phase 2 · France, Hungary, Italy, Poland · 16 sites
Registry update: 24 Aug 2026
NCT07221500
Recruiting
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Phase 2 · France, United Kingdom, Italy, Poland, United States · 43 sites
Registry update: 3 Nov 2026
NCT07099443
Recruiting
Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
Not applicable · France · 14 sites
Registry update: 8 Jul 2026

Ordered by registry start date. Freshness and sponsorship never change the order.